MarketVIEW Hospital & AMR Vaccines  ·  November 2024 edition

Staphylococcus aureus (MRSA)
BSI/SSI Vaccines Forecast, USA

S. aureus colonizes up to 60% of the population and remains a leading cause of bloodstream infections and surgical site infections in US hospitals, yet vaccine development has now suffered two major clinical failures in a row. Pfizer's SA4Ag missed in 2018, and GSK's follow-on candidate SA5Ag has now failed too. This is the independent commercial assessment of what a workable S. aureus vaccine could still be worth, drawing on VacZine Analytics' long-standing, independent authority in Hospital and AMR vaccine markets.

GSK SA5Ag Also Failed (2026) 30-60% Population Colonized US Surgical & ESRD Focus HHS Action Plan Priority Pathogen
Product catalogue
VAMV002
November 2024 edition

Format
PDF (~195 slides) + Excel
Coverage
USA, surgical & ESRD
Vaccines assessed
Pfizer SA4Ag, GSK SA5Ag, IBT-V02
Populations
Elective surgery, hemodialysis (ESRD)
Approach
Scenario-based
Base edition
November 2024
Availability
Syndicated / bespoke
30-60%
Of the population colonized
with S. aureus (permanent/intermittent)
119,247
US S. aureus bloodstream infections
in 2017 (CDC, most recent count)
20-50%
Mortality rate for
MRSA bacteraemia
2026
Year GSK's SA5Ag became the
field's second major vaccine failure
Disease background

Why S. aureus has remained a stubborn vaccine target

Staphylococcus aureus is among the most consequential pathogens in modern healthcare, and one of the most disappointing for vaccine developers. Understanding both the scale of the clinical burden and why two of the field's most advanced candidates have now failed is central to understanding what a workable vaccine could still be worth.

Peer-reviewed & 2026 pipeline data

Pathogen overview - Staphylococcus aureus and MRSA

Staphylococcus aureus is a Gram-positive, toxin-forming bacterium and a widespread human commensal, colonizing approximately 30 to 60% of the population, either permanently or intermittently. S. aureus is responsible for a wide range of clinical syndromes, from high-mortality bloodstream infections (BSIs) to community-based skin and soft tissue infections (SSTIs) such as skin abscesses. It is also a common cause of healthcare-associated infections (HAIs), including pneumonia and surgical site infections (SSIs). An antibiotic-resistant form, methicillin-resistant S. aureus (MRSA), has become a major problem both in and out of hospital, with substantial associated economic burden.

CDC's most recent comprehensive national estimate found 119,247 S. aureus bloodstream infections in the United States in 2017, with 19,832 associated deaths, spanning both MRSA and methicillin-susceptible S. aureus (MSSA). MRSA bacteraemia alone carries a mortality rate of approximately 20 to 50%, among the most lethal common healthcare-associated infections. CDC's most recent Antimicrobial Resistance Threats update (2021 to 2022, published July 2024) found that hospital-onset MRSA bloodstream infection rates, having risen during the COVID-19 pandemic, had returned toward pre-pandemic levels by 2022, a notable exception among the resistant pathogens tracked, most of which remained elevated.

S. aureus vaccines that prevent or reduce the impact of infection are greatly needed, although it is now accepted that a universal vaccine capable of addressing all infection types and reducing colonization is likely an unrealistic goal, given the pathogen's array of immune-evasion mechanisms. Development has instead focused on narrower, high-risk populations, and it has still been thwarted by repeated high-profile failures. Pfizer terminated its multicomponent candidate SA4Ag in 2018 after its Phase 2b/3 STRIVE trial, run in elective open posterior spinal fusion surgery patients, failed to demonstrate efficacy. GSK subsequently advanced a five-antigen adjuvanted candidate, SA5Ag (GSK3878858A), targeting recurrent SSTIs; results published in March 2026 in Clinical Infectious Diseases showed a vaccine efficacy of minus 38.1% at 12 months, worse than placebo, despite the vaccine generating robust functional immune responses against three of its five antigens.

With both of the field's most advanced candidates now having failed, development activity has shifted to earlier-stage, differently constructed multivalent toxoid vaccines. Integrated Biotherapeutics' heptavalent toxoid candidate IBT-V02, backed by CARB-X and Novo Holdings, entered Phase 1 testing in 2024/2025 with results anticipated from the second half of 2025, targeting both surgical MRSA prevention and recurrent SSTI. Chinese developer Olymvax's rFSAV and other early-stage multivalent programmes round out a field that is materially earlier in development than it was five years ago.

2026 119,247 US bloodstream infections (2017)  |  up to 50% MRSA bacteraemia mortality  |  Pfizer SA4Ag (2018) and GSK SA5Ag (2026) both failed  |  IBT-V02 now the most advanced active candidate
Product & competitor landscape

Two major vaccine failures - and a much earlier-stage field

The two most clinically advanced S. aureus vaccine candidates of the last decade have both now failed to protect the populations they were designed for. What remains is a materially earlier-stage field, built around differently constructed multivalent toxoid vaccines rather than the adjuvanted subunit approach both Pfizer and GSK pursued.

  • PfizerTerminated 2018
    SA4Ag
    A four-antigen multicomponent vaccine that reached Phase 2b/3 with fast-track designation, aimed at preventing S. aureus BSIs and SSIs in patients undergoing elective open posterior spinal fusion. The pivotal STRIVE trial failed to demonstrate efficacy and Pfizer terminated the programme in 2018.
  • GSKFailed 2026
    SA5Ag (GSK3878858A)
    A five-antigen, AS01E-adjuvanted vaccine (staphylococcal protein A, alpha-haemolysin, capsular polysaccharides CP5/CP8, and ClfA) targeting recurrent SSTIs. Results published March 2026 showed a vaccine efficacy of minus 38.1% at 12 months post-second dose, worse than placebo, despite generating robust immune responses against three antigens.
  • Chengdu OlymvaxPhase 3
    rFSAV 73.25% VE confirmed, Oct 2026
    A recombinant, E. coli-produced multivalent S. aureus vaccine trialled in elective-surgery patients across 60+ centres in China. On 11 July 2026, Olymvax (Shanghai-listed, 688319.SH) disclosed Phase 3 unblinding results showing 73.25% protective efficacy against its pre-specified 60% target, with a favourable safety profile reported through 365 days. The company has since publicly rebutted unverified online allegations of data irregularities and stated it will pursue regulatory filing; the result is company-reported and not yet independently confirmed by a regulator, and the trial population is China-based rather than USA. On 19-20 October 2026, Olymvax's follow-up stock-exchange disclosure released the full Phase 3 summary clinical study report, for the prevention of S. aureus infection following closed-fracture orthopaedic surgery, confirming the primary endpoint with statistical significance (hazard ratio 0.27, 95% CI 0.13-0.54; one-sided p=0.0001) consistent across age and sex subgroups; the company states further pharmaceutical, toxicology and commercial-scale manufacturing validation work is still required before a marketing application can be filed, with approval timing and outcome uncertain.
  • Integrated BiotherapeuticsPhase 1
    IBT-V02 Heptavalent toxoid
    A seven-antigen toxoid vaccine (TSST-1, PVL LukF/LukS, LukAB, staphylococcal enterotoxins A and B, and alpha-haemolysin), targeting both surgical MRSA prevention and recurrent SSTIs. Backed by CARB-X and Novo Holdings, entering Phase 1 with results anticipated from the second half of 2025.
  • LimmaTech Biologics (acquired by Eli Lilly)Phase 1
    LBT-SA7 Acquired by Lilly, May 2026
    A multivalent toxoid vaccine candidate targeting S. aureus skin and soft tissue infection and surgical-site infection, FDA Fast Track-designated, with first participants dosed in a Phase 1 study in February 2025. On 26 May 2026, Eli Lilly announced its acquisition of LimmaTech for up to $780 million as part of a three-company infectious-disease buying spree, the field's first major pharma re-entry since the SA4Ag and SA5Ag failures.
  • Second-wave & smaller programmesEarly-stage
    Other multivalent and virulence-factor candidates
    Additional earlier-stage multivalent programmes globally round out a field-wide pivot toward multi-mechanism toxoid and virulence-factor vaccines following the SA4Ag and SA5Ag failures.
Market reset
2026

GSK's SA5Ag failure is the second major clinical setback for S. aureus vaccines in less than a decade, following Pfizer's 2018 termination of SA4Ag, and it leaves Western development activity concentrated in materially earlier-stage, differently constructed candidates such as IBT-V02 and LimmaTech's LBT-SA7, both still in Phase 1. Eli Lilly's May 2026 acquisition of LimmaTech, for up to $780 million, is the first sign of major-pharma capital re-entering the space since the failures. The most clinically advanced signal instead now comes from China, where Olymvax's rFSAV posted a company-reported 73.25% Phase 3 topline efficacy in July 2026, though this remains unconfirmed by a regulator and outside the US surgical/ESRD populations modelled here. The underlying US opportunity has not gone away: S. aureus BSIs and SSIs remain a leading cause of US healthcare-associated morbidity and mortality, concentrated in identifiable high-risk surgical and renal populations. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-recovery scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW S. aureus BSI/SSI analysis combines a sophisticated procedure-level uptake methodology with the post-2026 competitor landscape and scenario-based revenue forecasting across US surgical and end-stage renal disease (ESRD) patient populations.

Procedure-level patient forecast

A sophisticated uptake methodology assigning surgical procedures a priority level alongside US state-level HO-MRSA risk, reconciling complex overlapping datasets into discrete eligible vaccine populations.

Competitor & pipeline review

Pfizer's 2018 SA4Ag termination, GSK's 2026 SA5Ag failure, and the emerging field of earlier-stage multivalent toxoid candidates including IBT-V02 and Olymvax's rFSAV.

Vaccinology & R&D strategy

Assessment of adjuvanted subunit versus multivalent toxoid approaches, and why the field's most advanced candidates have repeatedly fallen short.

Scenario-based revenue forecasts

Base, upside and conservative scenarios for US surgical and ESRD populations, with explicit assumptions on pipeline recovery timing.

Disease burden & epidemiology

Latest US MRSA/MSSA epidemiology drawing on CDC's Emerging Infections Program (EIP) and National Healthcare Safety Network (NHSN) surveillance data.

Prevention & legislative landscape

Review of prevention efforts and the HHS National Action Plan for Combating Antibiotic-Resistant Bacteria, and their implications for vaccine uptake.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and state-level HO-MRSA risk data are in the licensed model.

Target populationGeographySettingVaccine profileRevenue scenario
Elective open posterior spinal fusionUSASurgical (elective)Prophylactic, pre-surgicalModelled
ESRD / haemodialysis patientsUSAChronic careProphylacticModelled
High HO-MRSA risk US statesState-levelHospital-onsetRisk-adjusted uptakeModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseUSAAllAll profiles$███m
Full model in the licensed workbook
USA · surgical + ESRD · state-level risk · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the US S. aureus BSI/SSI vaccine opportunity.

  • Executive presentation (~195 slides, PDF) - disease background, epidemiology, the SA4Ag and SA5Ag failures, competitor pipeline, prevention/legislative review and full commercial assessment with supporting narrative and references
  • Comprehensive MS-Excel forecast workbook - scenario-based volume and revenue outputs for US surgical and ESRD populations, with state-level HO-MRSA risk adjustment
  • Scenario-based commercial forecasts - base, upside and conservative cases reflecting the post-2026 pipeline reset
  • Competitor intelligence - Pfizer SA4Ag, GSK SA5Ag, Integrated Biotherapeutics IBT-V02, and other early-stage multivalent programmes
  • Updated epidemiology module - CDC EIP and NHSN surveillance data on MRSA/MSSA bloodstream infections and surgical site infections
  • Prevention & policy review - the HHS National Action Plan for Combating Antibiotic-Resistant Bacteria and its implications for vaccine adoption
Target audience

Built for organisations weighing the S. aureus opportunity

Most valuable to teams evaluating the S. aureus BSI/SSI vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of the SA4Ag and SA5Ag failures and what they mean for the earlier-stage candidates left standing.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for S. aureus candidates at any stage.

Corporate strategy & BD

Validate the market size and structure after two major failures, and understand what it means for earlier-stage competitors.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on S. aureus and adjacent Hospital/AMR vaccine assets.

Hospital & infection control programmes

Demand modelling and prevention-strategy context for hospital epidemiology and infection control teams.

Researchers & academia

Comprehensive epidemiology and vaccine landscape for grant and translational planning, including the SA4Ag and SA5Ag trial findings.

Market access & policy

Pricing benchmarks and access-pathway assumptions in the context of the HHS antibiotic-resistance action plan.

About this analysis · VAMV002

VacZine Analytics has tracked Hospital and AMR vaccine markets since our earliest editions, positioning us to reassess the S. aureus BSI/SSI opportunity the moment the pipeline changed. This analysis combines a rigorous epidemiological and clinical review with a procedure-level commercial model spanning US surgical and ESRD populations that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis.

This November 2024 edition incorporates the full detail of Pfizer's SA4Ag termination and has been updated to reflect GSK's March 2026 publication of SA5Ag's Phase 1/2 results. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV002 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc S. aureus analysis, a briefing call is included on request.